Another Generic Lidocaine Patch Launched in US

Mylan has launched its lidocaine patch 5%, the generic version of Endo Pharmaceutical's Lidoderm.

Mylan has launched its lidocaine patch 5%, the generic version of Endo Pharmaceutical’s Lidoderm.

The topical product is approved as a local anesthetic for the relief of pain associated with post-herpetic neuralgia.

Mylan CEO Heather Bresch explained in a press release that the drug “comes in the form of a thin, lightweight patch and offers patients a high quality, affordable treatment option within the pain management space.”

The launch of Mylan’s lidocaine patch 5% follows Actavis’s initial generic version.

Some side effects associated with topical lidocaine include blistering, bruising, itching, and swelling. More adverse events may include seizures, irregular breathing, fast heartbeat, and fever.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.